Stay updated on MAPP2 MDMA Therapy Clinical Trial
Sign up to get notified when there's something new on the MAPP2 MDMA Therapy Clinical Trial page.

Latest updates to the MAPP2 MDMA Therapy Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedThe sponsor line now shows Resilient Pharmaceuticals as sponsor and responsible party, replacing Lykos Therapeutics. This change reflects a shift in the organization overseeing the study.SummaryDifference0.2%

- Check19 days agoChange DetectedThe page’s footer revision marker was updated from v3.5.2 to v3.5.3, indicating a general platform/version change without affecting the listed clinical trial study information.SummaryDifference0.0%

- Check26 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check55 days agoChange DetectedTemplate revision updated to v3.5.0, replacing v3.4.3. No user-facing content or study data are affected.SummaryDifference0.0%

- Check62 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check90 days agoChange DetectedRevision: v3.4.2 appears on the page, and previous revision notices (v3.4.1) and related funding notices have been updated or removed. These are administrative site updates and do not modify the study content or how users interact with the page.SummaryDifference0.4%

Stay in the know with updates to MAPP2 MDMA Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MAPP2 MDMA Therapy Clinical Trial page.